对乙酰氨基酚用于脓毒症危重患者器官功能障碍的预防与治疗:ASTER随机临床试验
ASTER为2b期随机双盲安慰剂对照试验,2021年10月至2023年4月在美国40家学术医院急诊科或ICU纳入447例脓毒症伴呼吸或循环器官功能障碍成人,随机接受对乙酰氨基酚1 g静脉每6小时或安慰剂共5天。主要终点28天内无器官支持存活天数在对乙酰氨基酚组为20.2天(95%CI 18.8-21.6),安慰剂组为19.6天(95%CI 18.2-21.0),差异0.6天(95%CI -1.4至2.6,P=0.56),无统计学意义。对乙酰氨基酚安全,肝酶、低血压和液体平衡无组间差异;15项次要终点中,第2至4天总SOFA、呼吸SOFA和凝血SOFA评分在对乙酰氨基酚组显著更低,7天内ARDS发生率对乙酰氨基酚组2.2% vs 安慰剂组8.5%(P=0.01,差异-6.3%,95%CI -10.8至-1.8)。
要点
- 主要终点28天内无器官支持存活天数:对乙酰氨基酚组20.2天(95%CI 18.8-21.6)vs 安慰剂组19.6天(95%CI 18.2-21.0),差异0.6天(95%CI -1.4至2.6),P=0.56,未达统计学显著。
- 对乙酰氨基酚1 g静脉每6小时共5天安全,肝酶、低血压和液体平衡与安慰剂组无差异。
- 7天内ARDS发生率对乙酰氨基酚组2.2% vs 安慰剂组8.5%(P=0.01,差异-6.3%,95%CI -10.8至-1.8)。
- 第2至4天总SOFA、呼吸SOFA和凝血SOFA评分在对乙酰氨基酚组显著低于安慰剂组。
- 游离血红蛋白水平(>10 mg/dL)与对乙酰氨基酚之间无显著交互作用。
适用人群与场景
- 成人脓毒症伴呼吸或循环器官功能障碍,在就诊后36小时内在急诊科或ICU纳入。
诊断标准与关键阈值
- 脓毒症诊断依据未在原文详述;纳入标准为成人脓毒症伴呼吸或循环器官功能障碍。
- 随机前血浆游离血红蛋白水平>10 mg/dL用于评估对乙酰氨基酚的疗效修饰作用。
处置流程与药物剂量
- 对乙酰氨基酚1 g静脉每6小时,共5天;或安慰剂。
研究设计与关键结果
- 2b期随机双盲安慰剂对照试验,2021年10月至2023年4月在美国40家学术医院急诊科或ICU纳入447例成人脓毒症伴呼吸或循环器官功能障碍患者,随访90天;对乙酰氨基酚组227例,安慰剂组220例;平均年龄64岁(SD 15),女性51%,平均SOFA评分5.4(SD 2.5)。
- 主要终点28天内无器官支持(机械通气、血管升压药和肾脏替代治疗)存活天数:对乙酰氨基酚组20.2天(95%CI 18.8-21.6)vs 安慰剂组19.6天(95%CI 18.2-21.0),差异0.6天(95%CI -1.4至2.6),P=0.56。
- 对乙酰氨基酚安全,肝酶、低血压和液体平衡无组间差异。
- 15项次要终点中,第2至4天总SOFA、呼吸SOFA和凝血SOFA评分在对乙酰氨基酚组显著降低;7天内ARDS发生率对乙酰氨基酚组2.2% vs 安慰剂组8.5%(P=0.01,差异-6.3%,95%CI -10.8至-1.8)。
- 游离血红蛋白水平与对乙酰氨基酚之间无显著交互作用。
证据类型、等级与局限
- 证据类型:2b期随机、双盲、安慰剂对照临床试验(RCT)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 静脉对乙酰氨基酚1 g每6小时共5天未显著改善脓毒症危重患者28天内无器官支持存活天数,不能据此将其作为改善该终点的常规治疗。
- 对乙酰氨基酚在该人群中安全,肝酶、低血压和液体平衡与安慰剂无差异。
- 对乙酰氨基酚组第2至4天总SOFA、呼吸SOFA和凝血SOFA评分显著更低,7天内ARDS发生率对乙酰氨基酚组2.2% vs 安慰剂组8.5%(P=0.01)。
- 作者结论:静脉对乙酰氨基酚安全,但未显著改善脓毒症危重患者无器官支持存活天数。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Acetaminophen (paracetamol) has many pharmacological effects that might be beneficial in sepsis, including inhibition of cell-free hemoglobin-induced oxidation of lipids and other substrates.
OBJECTIVE: To determine whether acetaminophen increases days alive and free of organ dysfunction in sepsis compared with placebo.
DESIGN, SETTING, AND PARTICIPANTS: Phase 2b randomized, double-blind, clinical trial conducted from October 2021 to April 2023 with 90-day follow-up. Adults with sepsis and respiratory or circulatory organ dysfunction were enrolled in the emergency department or intensive care unit of 40 US academic hospitals within 36 hours of presentation.
INTERVENTION: Patients were randomized to 1 g of acetaminophen intravenously every 6 hours or placebo for 5 days.
MAIN OUTCOME AND MEASURES: The primary end point was days alive and free of organ support (mechanical ventilation, vasopressors, and kidney replacement therapy) to day 28. Treatment effect modification was evaluated for acetaminophen by prerandomization plasma cell-free hemoglobin level higher than 10 mg/dL.
RESULTS: Of 447 patients enrolled (mean age, 64 [SD, 15] years, 51% female, mean Sequential Organ Failure Assessment [SOFA] score, 5.4 [SD, 2.5]), 227 were randomized to acetaminophen and 220 to placebo. Acetaminophen was safe with no difference in liver enzymes, hypotension, or fluid balance between treatment arms. Days alive and free of organ support to day 28 were not meaningfully different for acetaminophen (20.2 days; 95% CI, 18.8 to 21.6) vs placebo (19.6 days; 95% CI, 18.2 to 21.0; P = .56; difference, 0.6; 95% CI, -1.4 to 2.6). Among 15 secondary outcomes, total, respiratory, and coagulation SOFA scores were significantly lower on days 2 through 4 in the acetaminophen arm as was the rate of development of acute respiratory distress syndrome within 7 days (2.2% vs 8.5% acetaminophen vs placebo; P = .01; difference, -6.3; 95% CI, -10.8 to -1.8). There was no significant interaction between cell-free hemoglobin levels and acetaminophen.
CONCLUSIONS AND RELEVANCE: Intravenous acetaminophen was safe but did not significantly improve days alive and free of organ support in critically ill sepsis patients.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04291508.
参考来源
- Ware LB, Files DC, Fowler A, et al. Acetaminophen for Prevention and Treatment of Organ Dysfunction in Critically Ill Patients With Sepsis: The ASTER Randomized Clinical Trial. JAMA. 2024. PMID: 38762798. doi:10.1001/jama.2024.8772
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。